Preventing post-stroke dementia. The MARCH Trial. Protocol and statistical analysis plan of a randomized clinical trial testing the safety and efficacy of Maraviroc in post-stroke cognitive impairment

CONCLUSIONS: The results of this work could lead to a novel, readily available, therapeutic avenue to reduce PSCI, and possibly other pathologies. This study will test safety and effectiveness of Maraviroc in limiting cognitive deterioration and/or post stroke cognitive impairment in patients with cerebral small vessel disease.SCHEDULE: First-patient first-visit was May 2021. Recruitment to complete in 2023, follow-up to complete in 2024.PMID:36082248 | PMC:PMC9446318 | DOI:10.1177/23969873221098857

Source: Atherosclerosis - September 9, 2022 Category: Cardiology Authors: Einor Ben Assayag Jeremy Molad Estelle Seyman Ofer Rotschild Ehud Zeltzer Udi Sadeh-Gonik Noa Bregman Aviva Alpernas Yahel Segal Dafna Ben Bashat Talya Nathan Muhamad Hawwari Oren Tene Hen Hallevi Source Type: research